Seribantumab

Edit links
Source: Wikipedia, the free encyclopedia.
Seribantumab
HER3
Clinical data
Other namesMM-121
ATC code
  • none
Identifiers
CAS Number
IUPHAR/BPS
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6340H9810N1690O1986S52
Molar mass143151.18 g·mol−1

Seribantumab (

NRG1 binding and thereby preventing the activation of the receptor.[3]

This drug was developed by Sanofi/Merrimack Pharmaceuticals, Inc.

References

  1. ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108" (PDF). WHO Drug Information. 26 (4).
  2. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Seribantumab, American Medical Association.
  3. PMID 36140214
    .
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Seribantumab&oldid=1188037068"